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nel through theNa channel’s supposed calcium sensitivity.
While there are proponents for both sides, there has been
relatively little research that provides strong evidence for
either case. In this experiment, the effect of calmodulin on
NaV 1.5 is tested by preparing a set of cardiac cells (of the
human specie) with the NaV 1.5 C-Termini and CaM pro-
tein, whichwere then to be placed in solutionswith varying
concentrations of calcium.We took special care to test mul-
tiple concentrations of calcium, as previous studies have
tested very low concentrations, with Manu Ben-Johny’s
team from the JohnHopkins laboratory in particular testing
up to a meager 50 micromolar, despite producing a well-
respected paper (By comparison, the average Na channel
can naturally sustain a concentration of almost 1-2millimo-
lar and on someoccasions, reaching evenhigher concentra-
tions). After using light scattering and observing the signals
given off by the calcium interactingwith theseNav1.5/CaM
complexes across the varying calcium concentrations, the
overall pattern indicated that there was a one to one stoi-
chiometry between calmodulin and Nav 1.5. More impor-
tantly, it indicated calcium sensitivity of the Na channel.
With this research, a definitive answer has been drawn
regarding the importanceof calmodulin in calciummodula-
tion in Na channels. Not only does this have the effect of
creating a foundation for further research into the structure
and function of Na channels, but it also gives deep insight
into fundamental functions of the channel that can play a
major role into the creation of drugs to treat the many car-
diac diseases associated with dysfunction of the channel.
http://dx.doi:10.1016/j.jsha.2016.04.044
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44. Copeptin as early marker of acute non-ST
elevation myocardial infarction in patients
suspected with acute coronary syndrome
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Rapid diagnosis and management of AMI have great
impact on morbidity and mortality. Diagnosis which is
based on elevation of cardiac biomarkers has its limita-
tions. Copeptin is the C-terminal part of the vasopressin
prohormone. The pathophysiology mode of release
should theoretically add diagnostic information of car-
diac cell necrosis. One of the major limitations of cardiac
biomarkers is the delayed release in circulation. So look-
ing for a new marker with a short diagnostic time window
is needed. Aim is to determine the role of copeptin as an
early marker for acute non-ST elevation MI (NSTEMI).
This study included 88 patients with chest pain. They
were divided into 2 groups. Group (1); included 30
patients with diagnosis of NSTEMI. Diagnosis of AMI
was established according to the universal definition of
MI. Group (2); included 58 patients with diagnosis of
unstable angina (UA). Full medical history, physical
examination, 12 lead ECG, random blood glucose level,
renal function, total cholesterol, triglyceride, cardiac tro-
ponin I and Copeptin were obtained on admission. Fol-
low up cardiac troponin I was done. Inclusion criteria:
Defined as chest pain of 66 h duration since onset, sug-
gestive of myocardial ischemia, and lasting >20 min. at
rest. Exclusion criteria: Patients with positive First cardiac
troponin were rolled out, patients with ST segment eleva-
tion were rolled out. Other exclusion criteria: Patients
presenting after a cardiac arrest, Trauma or major sur-
gery within the last 4 week; pregnancy; IV drug abuse;
age less than 18 years; shock and sepsis. Patients who
were included had second troponin I re- done and copep-
tin analysis done. In group 1 (NSTEMI) 28 patients had
ECG changes and only 2 had NSTEMI without ECG
changes. In group 2 (UA) 23 patients had ECG changes
and 35 patients had normal ECG. Males and females
were 49 and 39. Age in G1 and G2 was 60 ± 4 and
53 ± 5. Copeptin analysis was done 6 h after Infarction
or chest pain. All the patients with NSTEMI (30) had
positive copeptin and positive troponin except one only
who had + troponin only and another one who had +
copeptin only. Of the 58 patients without MI none had
the two tests positive, only one had + troponin and one
had + copeptin. Using ROC curve: copeptin had sensitiv-
ity 100% and specificity 82.8% with using cut off point
13.2 pmol/l. So copeptin can be used for early detection
of myocardial infarction. Copeptin seems to be an ideal
confirmatory marker for rapid rule out of AMI. If the
two tests (with troponin) are positive, this is evident
MI; if the two are negative it rules out MI.
http://dx.doi:10.1016/j.jsha.2016.04.045
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45. Ezetimibe and statins yields on silent holter
ambulatory myocardial ischemia
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Further cholestrol lowering may affect silent ischemia
detected on holter monitoring. Cholesterol lowering is
associated with a reduction in cardiovascular morbidity
and mortality. Statins are the main drugs for cholesterol
lowering. Ezetimibe when added to statins gives further
reduction in cholesterol but its long-term effect on cardi-
ovascular morbidity and mortality and ischemic events is
not known. This study sought to determine whether
further cholesterol lowering with ezitimibe will also
results in a reduction of myocardial ischemia during daily
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life. We enrolled 50 patients with proven stable coronary
artery disease (CAD) and at least one episode of ST-
segment depression on ambulatory ECG monitoring.
All of them were receiving optimal therapy for CAD
including statin therapy for cholesterol reduction. 25
patients were randomized to continue their statin ther-
apy (Statin only group) and 25 to recieve statin plus ezi-
timibe 10 mg/day (ezitimibe group). Serum cholesterol
and LDL cholesterol levels and ambulatory monitoring
were repeated after 4–6 months of therapy. The two
groups were comparable with respect to baseline charac-
teristics, number of episodes of ST-segment depression,
and baseline serum cholesterol levels. The ezitimibe
group had lower mean total and LDL cholesterol levels
at study end and experienced a significant reduction in
the number of episodes of ST-segment depression com-
pared with the statin only group. ST-segment depression
was completely resolved in 13 of 25 patients (52%) in the
ezitimibe group versus 3 of 25 (12%) in the statin only
group. The ezitimibe group exhibited a highly significant
reduction in ambulatory ischemia (P < .001). By logistic
regression, treatment with ezitimibe was an independent
predictor of ischemia resolution. Further cholesterol low-
ering with ezitimibe can result in reduction or resolution
of myocardial ischemia recorded as episodes of ST-
segment depression in ambulatory monitoring of the
ECG.
http://dx.doi:10.1016/j.jsha.2016.04.046
46. Is visualization of totally occluded left anterior
descending coronary artery on CT images before
coronary artery bypasses grafting has beneficial
effect?
H. Alshehri
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Computed tomography coronary angiography (CTCA)
has emerged as an accurate anatomic method for detec-
tion of coronary arteries. The use of the left internal
mammary artery (LIMA) to bypass the left anterior des-
cending artery (LAD) is the ‘‘gold standard’’ of coronary
artery revascularization. Assessment of graftability of the
LAD artery is an important factor before planning coron-
ary artery bypasses grafting (CABG). Coronary angiogra-
phy could not visualize left anterior descending after
proximal totally occluded segment in some patients with
coronary artery disease. CTCA could identify the flow
distal to the total occlusion better than coronary
angiography.
Objective: To assess if CTCA has beneficial effect in
deciding the graftability of LAD artery.
Methods: Coronary angiography was undertaken in 11
patients because of chest pain. Although coronary angio-
graphy could not visualize LAD artery distal to proximal
total occlusion. Delineation of the LAD artery was
achieved on CTCA. All patients underwent CABG with
LIMA to LAD artery.
Conclusion: CTCA in addition to coronary angiography
is valuable tool to assess graftability of LAD artery before
CAB.
http://dx.doi:10.1016/j.jsha.2016.04.047
Arrhythmias and electrophysiology
ARRHYTHMIA: CLINICAL ELECTROPHYSIOLOGY, DIAG-
NOSIS AND RISK STRATIFICATION
47. A cardiac center experience with Brugada
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Brugada syndrome is a heritable arrhythmia syn-
drome that is characterized by an electrocardiographic
pattern consisting of coved-type ST-segment elevation
(2 mm) followed by a negative T wave in the right precor-
dial leads, V1 through V3 (often referred to as type 1 Bru-
gada electrocardiographic pattern), here we describe 3
cases of Brugada who survived sudden cardiac death
(SCD) cardiac center experience with survived Brugada
syndrome patients – case series. First Case: The Father
45 years old male, presented in 2005 after involvement
in unprovoked motor vehicle accident, the patient was
the driver who lost consciousness and rushed to the hos-
pital. On arrival to our ER and putting the patient on the
bed, the ER doctor observed a brief episode of VF on the
monitor. The patient was taken to the catheterization
Lab, his coronaries were normal. The diagnosis of Bru-
gada was established and the patient received a defibril-
lator. At That Time all family members were screened
and were negative. Second Case: The Son of the first
patient 5 years later his 23 years old male rushed to our
ER after he lost consciousness, he was passenger in the
car of his friend. Third Case: The pilot A military pilot
aged a male 35 years old was in very good health when
he lost consciousness and brought to the hospital after
resuscitation in 2005. He had full invasive cardiac evalua-
tion, subsequently he received a defibrillator in the same
admission period, till 2015 he is doing fine. Brugada syn-
drome is associated with high tendency for sudden car-
diac death. In our three cases the first clinical
presentation was survived sudden cardiac death (SCD)
and all three male patients survived. We did not encoun-
ter a female patient who survived sudden cardiac death.
http://dx.doi:10.1016/j.jsha.2016.04.048
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